Table of Contents
MAPLE GROVE, Minn. – Upsher-Smith announced the recent launch of mesalamine extended-release capsules, USP 375 mg. The mesalamine capsule market had U.S. sales of approximately $105 million for the 12 months ending June
2023 according to IQVIA. Upsher-Smith’s mesalamine extended-release capsules are AB-rated to APRISO (mesalamine) extended-release capsules.
Product Information
| Product | Strength | NDC # | Package Size |
| Mesalamine extended-release capsules, USP | 375 mg | 0832-6056-12 | 120-count bottle |
